Search / Trial NCT00000659

A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of December 10, 2023

Terminated

Keywords

Acquired Immunodeficiency Syndrome Antigens, Cd4 Aids Related Complex Zidovudine

Description

AZT has been shown to be effective in the treatment of AIDS and advanced ARC but not without toxicity. The most clinically significant toxicity is dose related inhibition of bone marrow function. Furthermore, HIV-1 isolates from patients treated for more than 6 months with AZT have now been found which appear to have reduced sensitivity to AZT. The incidence of toxicity and occurrence of virus with reduced sensitivity to AZT may result in the inability to administer AZT long-term to patients with AIDS and advanced ARC. Recombinant soluble CD4 (rCD4) has shown antiretroviral effects and has ...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Nystatin or clotrimazole for suppression of oral thrush.
  • Aerosolized pentamidine as chemoprophylaxis for Pneumocystis carinii pneumonia (PCP).
  • Trimethoprim / sulfamethoxazole (TMP / SMX) for patients who are clinically and hematologically stable on TMP / SMX PCP prophylaxis.
  • Patients must have the following:
  • Diagnosis of AIDS or advanced AIDS related complex (ARC).
  • CD4 cell count < 300 cells/mm3.
  • Ability to understand and sign the consent form.
  • Risk Behavior:
  • Allowed:
  • History of drug abuse with current abstinence or enrollment in a methadone treatment program.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions or symptoms are excluded:
  • Malignancies other than Kaposi's sarcoma.
  • AIDS dementia which, in the opinion of the investigator, precludes patients from giving fully informed consent or from complying fully with the requirements of this protocol.
  • Active infection with an opportunistic pathogen requiring ongoing therapy.
  • Preexisting antibodies to rCD4.
  • Concurrent Medication:
  • Excluded:
  • Investigational drugs.
  • Antiretroviral agents such as dextran sulfate or AL721.
  • Cytotoxic chemotherapy.
  • Concurrent Treatment:
  • Excluded:
  • Radiation therapy.
  • Patients with the following are excluded:
  • Malignancies other than Kaposi's sarcoma.
  • AIDS dementia which, in the opinion of the investigator, precludes patients from giving fully informed consent or from complying fully with the requirements of this protocol.
  • Active infection with an opportunistic pathogen requiring ongoing therapy.
  • Preexisting antibodies to rCD4.
  • Prior Medication:
  • Excluded:
  • Zidovudine (AZT) for longer than 30 days or prior treatment with AZT for < 30 days if discontinued for toxicity due to AZT.
  • Excluded within 30 days of study entry:
  • Immunomodulators.
  • Previous participation in any group of another part of this study. For example, patients treated in Part 1A of this study may not reenter the study to be treated in Part 2.
  • Chemotherapy.
  • Prior Treatment:
  • Excluded within 30 days of study entry:
  • Radiation therapy.
  • Active use of illicit drugs or abuse of alcohol at time of protocol entry.

Attachments

readout_NCT00000659_2023-12-10.pdf

4.5 MB

NCT00000659_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

New York, New York, United States

New Orleans, Louisiana, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0